Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women

Gynecological Endocrinology

Volumn 26, Issue 8, 2010, Pages 612-616

  Ma, Linlin ^a   Lin, Shouqing ^a   Chen, Rong ^a   Wang, Xiuli ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Beijing Pinggu Maternity and Child Care Hospital   (China)

Author keywords

efficacy; premenstrual syndrome; symptom factor; Vitex agnus castus

Indexed keywords

AGNUSCATON; BNO 1095; CYCLODYNON; PLACEBO; UNCLASSIFIED DRUG; VITEX AGNUS CASTUS EXTRACT; HERBACEOUS AGENT;

ADULT; AFFECT; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TABLET; VITEX AGNUS CASTUS; WATER RETENTION; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; PHYTOTHERAPY; VITEX;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; PHYTOTHERAPY; PREMENSTRUAL SYNDROME; PROSPECTIVE STUDIES; VITEX;

EID: 77954780445     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513591003632126     Document Type: Article

References (23)

1. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988;33:340-346.
2. Singh BB, Berman BM, Simpson RL, Annchild A. Incidence of premenstrual symptome and remedy usage: a national probability sample study. Altern Ther Health Med 1998;4:75-79.
3. Zhao G, Wang L, Qu C. Prevalence of premenstrual syndrome in reproductive women and its influential factors. Clin J Obstet Gynecol 1998;33:222-224.
4. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines of management. J Psychiatry Neurosci 2000;45:459-468.
5. Qiao M, Zhang Z, Xu X, Han X, Ci Y, Ye Q. Epidemiological survey on syndromes distribution in PMS. Chin J Basic Med Traditional Chin Med 1997;3:31-33.
6. Keye WR Jr. General evaluation of premenstrual symptoms. Clin Obstet Gynecol 1987;30:396-407.
7. Mortola JF. Issues in the diagnosis and research of premenstrual syndrome. Clin Obstet Gynecol 1992;35:587-598.
8. Ramcharan S, Love EJ, Fick GH, Goldfien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol 1992;45:377-392.
9. Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001;104:110-116.
10. Taylor JW. Plasma progesterone, oestradiol 17 beta and premenstrual symptoms. Acta Psychiatr Scand 1979;60:76-86.
11. Seippel L, Eriksson O, Grankvist K, von Shoultz B, Backstrom T. Physical symptoms in premenstrual syndrome are related to plasma progesterone and desoxycorticosterone. Gynecol Endocrinol 2000;14:173-181.
12. Ellen WF, Karl R, Steven JS, Marcia P. Differential response to antidepressants in women with premenstrual syndrome/ premenstrual dysphoric disorder. Arch Gen Psychiatry 1999;56:932-939.
13. Ellen WF, Jabara S, Steven JS, Roxellen A. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med 2002;11:459-464.
14. Ho KY, Thorner MO. Therapeutic applications of bromcriptine in endocrine and neurological diseases. Drugs 1988;36: 67-82.
15. Wuttke W, Gorkow C, Jarry H. Dopaminergic compounds in Vitex agnus castus. In: Loew RN, Darmstadt D, editors. Phytopharmaka in Foschung und klinischer Anwendung: Steinkopff Verlag; 1995. pp 81-91.
16. KiIicdag EB, Tarim E, Bagis T, Erkanli S, Aslan E, Ozsahin K, Kuscu E. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Gynaecol Obstet 2004;85:292-293.
17. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of ciclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast 1999;8:175-181.
18. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol Clin Exp 2003; 18:191-195.
19. Lauritzen Ch, Reuter HD, Repges R, Böhnert KJ, Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-blind study vs. pyridoxine. Phytomedicine 1997;4:183-189.
20. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective,randomised, placebo controlled study. BMJ 2001;322:134-137.
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision ed. Washington: American Psychiatric Association; 2000. pp. 771-774.
22. Steiner M, Haskett RF, Carroll BJ. Premenstrual syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980;62:177-190.
23. Thys-Jaccobs S, Alvir J, Fratarcangelo P. Assessment and rating instrument: comparative analysis of three PMS assessment instruments- the identification of premenstrual syndrome with core symptoms. Psychopharmacol Bull 1995;31: 389-396.